• Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations 

      Boer, Cindy G.; Hatzikotoulas, Konstantinos; Southam, Lorraine; Stefánsdóttir, Lilja; Almeida, Rodrigo Coutinho de; Zhang, Yanfei; Wu, Tian T.; Zheng, Jie; Hartley, April; Teder-Laving, Maris; Skogholt, Anne Heidi; Terao, Chikashi; Zengini, Eleni; Alexiadis, George; Barysenka, Andrei; Bjornsdottir, Gyda; Gabrielsen, Maiken Elvestad; Gilly, Arthur; Ingvarsson, Thorvaldur; Johnsen, Marianne Bakke; Jonsson, Helgi; Kloppenburg, Margreet; Luetge, Almut; Lund, Sigrun H; Magi, Reedik; Mangino, Massimo; Nelissen, Rob G.H.H.; Shivakumar, Manu; Steinberg, Julia; Takuwa, Hiroshi; Thomas, Laurent; Tuerlings, Margo; Babis, George C.; Cheung, Jason Pui Yin; Kang, Jae Hee; Kraft, Peter; Lietman, Steven A.; Samartzis, Dino; Slagboom, P. Eline; Stefansson, Kari; Thorsteinsdottir, Unnur; Tobias, Jonathan H.; Uitterlinden, André G.; Winsvold, Bendik K S; Zwart, John Anker Henrik; Smith, George Davey; Sham, Pak Chung; Thorleifsson, Gudmar; Hveem, Kristian; Zeggini, Eleftheria (Peer reviewed; Journal article, 2021)
      Osteoarthritis affects over 300 million people worldwide. Here, we conduct a genome-wide association study meta-analysis across 826,690 individuals (177,517 with osteoarthritis) and identify 100 independently associated ...
    • Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition 

      Brumpton, Ben Michael; Fritsche, Lars; Zheng, Jie; Nielsen, Jonas Bille; Mannila, Maria Nastase; Surakka, Ida; Rasheed, Humaira; Vie, Gunnhild Åberge; Graham, Sarah E.; Gabrielsen, Maiken Elvestad; Laugsand, Lars Erik; Aukrust, Pål; Vatten, Lars Johan; Damås, Jan Kristian; Ueland, Thor; Janszky, Imre; Zwart, John-Anker; van't Hooft, Ferdinand M.; Seidah, Nabil Georges; Hveem, Kristian; Willer, Cristen; Smith, George Davey; Åsvold, Bjørn Olav (Peer reviewed; Journal article, 2019)
      PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. Although some long-term trials have evaluated their safety, ...